Denali Therapeutics Inc (DNLI) Review – Making Smarter Decisions

Denali Therapeutics Inc (NASDAQ: DNLI) is -19.85% lower on its value in year-to-date trading and has touched a low of $15.45 and a high of $33.31 in the current 52-week trading range. The question becomes, what are the chances the stock will make a comeback and enjoy potential growth. Why not look at analysts view on what the future holds for the stock. The DNLI stock was last observed hovering at around $16.95 in the last trading session, with the day’s gains setting it 0.25%.

Currently trading at $17.20, the stock is 0.29% and -9.71% below its SMA20 and SMA50 respectively. However, with a daily trading volume of 0.9 million and changing 1.47% at the moment leaves the stock -26.98% off its SMA200. DNLI registered -46.18% loss for a year compared to 6-month loss of -30.45%. The firm has a 50-day simple moving average (SMA 50) of $3.88 and a 200-day simple moving average (SMA200) of -$8.76.

Invest Like Buffett: Travel Back in Time & Grab This High-Potential Stock Before It Explodes

Imagine buying Apple for $1, Amazon for $2, or Tesla for $3. Now, imagine the same opportunity with a hidden gem trading under $3 right now.

Our premium newsletter, powered by AI and expert analysis, uncovers these time-travel investment opportunities.

Invest like Buffett and profit from undervalued gems before the market catches on.

Limited-time offer: Get your first month for just $2.90 and start your journey to wealth creation.


Sponsored

The stock witnessed a -12.87% gain in the last 1 month and extending the period to 3 months gives it a -18.98%, and is 4.94% up over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 4.99% over the week and 4.69% over the month.

Denali Therapeutics Inc (DNLI) has around 427 employees, a market worth around $2.38B and $340.81M in sales. Profit margin for the company is -36.51%. Distance from 52-week low is 11.33% and -48.36% from its 52-week high. The company has generated returns on investments over the last 12 months (-10.68%).

Denali Therapeutics Inc quarterly earnings per share for the current quarter are estimated at -$0.8 with sales reaching $8.36M over the same period.The EPS is expected to grow by 60.16% this year, but quarterly earnings will post 203.70% year-over-year. Quarterly sales are estimated to shrink -18.70% in year-over-year returns.

299 institutions hold shares in Denali Therapeutics Inc (DNLI), with institutional investors hold 94.97% of the company’s shares. The shares outstanding are 135.97M, and float is at 109.51M with Short Float at 9.03%. Institutions hold 81.03% of the Float.

The top institutional shareholder in the company is Baillie Gifford and Company with over 14.84 million shares valued at $438.04 million. The investor’s holdings represent 10.80% of the DNLI Shares outstanding. As of Jun 29, 2023, the second largest holder is Vanguard Group Inc with 10.24 million shares valued at $302.27 million to account for 7.45% of the shares outstanding. The other top investors are Blackrock Inc. which holds 10.11 million shares representing 7.36% and valued at over $298.24 million, while Wellington Management Group, LLP holds 5.12% of the shares totaling 7.04 million with a market value of $207.7 million.

Denali Therapeutics Inc (DNLI) Insider Activity

A total of 16 insider transactions have happened at Denali Therapeutics Inc (DNLI) in the last six months, with sales accounting for 15 and purchases happening 1 times. The most recent transaction is an insider sale by SATO VICKI L, the company’s Director. SEC filings show that SATO VICKI L sold 1,666 shares of the company’s common stock on Jan 16 at a price of $18.42 per share for a total of $30688.0. Following the sale, the insider now owns 0.12 million shares.

Denali Therapeutics Inc disclosed in a document filed with the SEC on Jan 10 that Ho Carole (Chief Medical Officer) sold a total of 4,668 shares of the company’s common stock. The trade occurred on Jan 10 and was made at $19.02 per share for $88785.0. Following the transaction, the insider now directly holds 0.15 million shares of the DNLI stock.

Still, SEC filings show that on Jan 09, Watts Ryan J. (President and CEO) disposed off 7,818 shares at an average price of $19.78 for $0.15 million. The insider now directly holds 2,268,363 shares of Denali Therapeutics Inc (DNLI).

Denali Therapeutics Inc (DNLI): Who are the competitors?

One of the company’s main competitors (and peers) include Pieris Pharmaceuticals Inc. (PIRS) that is trading -90.24% down over the past 12 months.Plandai Biotechnology Inc. (PLPL) lies in the list of competitors of the Denali Therapeutics Inc and is -33.33% lower over the same period from DNLI